期刊
MOLECULES
卷 25, 期 15, 页码 -出版社
MDPI
DOI: 10.3390/molecules25153337
关键词
multitarget drug discovery; MTDLs; tacrine; donepezil; AChE inhibitors; BACE-1 inhibitors; GSK-3 beta inhibitors
资金
- Priority Research Area qLife under the program Excellence Initiative-Research University at the Jagiellonian University in Krakow [06/IDUB/2019/94]
Despite tremendous research efforts at every level, globally, there is still a lack of effective drugs for the treatment of Alzheimer ' s disease (AD). The biochemical mechanisms of this devastating neurodegenerative disease are not yet clearly understood. This review analyses the relevance of multiple ligands in drug discovery for AD as a versatile toolbox for a polypharmacological approach to AD. Herein, we highlight major targets associated with AD, ranging from acetylcholine esterase (AChE), beta-site amyloid precursor protein cleaving enzyme 1 (BACE-1), glycogen synthase kinase 3 beta (GSK-3 beta),N-methyl-d-aspartate (NMDA) receptor, monoamine oxidases (MAOs), metal ions in the brain, 5-hydroxytryptamine (5-HT) receptors, the third subtype of histamine receptor (H(3)receptor), to phosphodiesterases (PDEs), along with a summary of their respective relationship to the disease network. In addition, a multitarget strategy for AD is presented, based on reported milestones in this area and the recent progress that has been achieved with multitargeted-directed ligands (MTDLs). Finally, the latest publications referencing the enlarged panel of new biological targets for AD related to the microglia are highlighted. However, the question of how to find meaningful combinations of targets for an MTDLs approach remains unanswered.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据